Amgen Wins in Kidney Drug Infringement Appeal
Written January 10, 2020
The US Court of Appeals for the Federal Circuit on January 7, 2020, vacated and remanded a lower court ruling which held that Amneal Pharmaceuticals LLC, an integrated specialty pharmaceutical company, didn’t infringe Amgen Inc.’s patent for the kidney disease drug Sensipar. Amgen Inc. v. Amneal Pharm., Fed. Cir., No. 16-853, 1/7/20.
Amgen, a biopharmaceutical company, sued Amneal, the Piramal Group, and Zydus Pharmaceuticals in an effort to block the three companies from bringing competing generic versions of their drug into the market.
The Federal Circuit affirmed the lower court’s ruling that Piramal’s product doesn’t infringe claims of the Amgen patent, while finding Zydus—which cross-appealed for its own generic product—is infringing the claims.
Amgen, a biopharmaceutical company, sued Amneal, the Piramal Group, and Zydus Pharmaceuticals in an effort to block the three companies from bringing competing generic versions of their drug into the market.
The Federal Circuit affirmed the lower court’s ruling that Piramal’s product doesn’t infringe claims of the Amgen patent, while finding Zydus—which cross-appealed for its own generic product—is infringing the claims.